Clinical Trial Update: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating asciminib monotherapy with dose escalation for first- and second-line chronic myeloid leukemia is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Asciminib (asciminib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia - Chronic Phase | Phase 2 | Status: ACTIVE_NOT_RECRUITING